Dose Reduction in Thoracic CT

This study has been completed.

First Received: September 12, 2005 Last Updated: April 20, 2007 History of Changes

Sponsored by:	University Health Network, Toronto
Information provided by:	University Health Network, Toronto
ClinicalTrials.gov Identifier:	NCT00188461

Purpose

Hypothesis: Does a 50% reduction in radiation in dose significantly affect the diagnostic quality of chest CT

Condition	Intervention	Phase
Lymphoma	Device: CT Thorax	Phase I

MedlinePlus related topics: Lymphoma

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Efficacy Study
Official Title:	Dose Reduction in Thoracic CT: A Comparison of on Line Automatic Dose Reduction and a 50% Reduction in Dose

Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:

Evaluating the diagnostic quality of thoracic CT exams performed at 50% of standard dose parameters

Estimated Enrollment:	100
Study Start Date:	January 2004
Estimated Study Completion Date:	August 2005

Detailed Description:

Patients with Lymphoma are recruited and have a follow up CT performed at 50% of the standard exposure parameters. The studies are compared for image quality with a recent (<3 months) thoracic CT performed at standard exposure parameters.

Eligibility

Ages Eligible for Study:	16 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with Lymphoma

Exclusion Criteria:

No recent (<3 months) thoracic CT

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00188461

Locations

Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada

Sponsors and Collaborators

University Health Network, Toronto

Investigators

Principal Investigator:

Narinder Paul, FRCP C

University Health Network, Toronto

More Information

No publications provided

Study ID Numbers:	03-0875
Study First Received:	September 12, 2005
Last Updated:	April 20, 2007
ClinicalTrials.gov Identifier:	NCT00188461 History of Changes
Health Authority:	Canada: Health Canada

Study placed in the following topic categories:

Lymphatic Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Lymphoma

Additional relevant MeSH terms:

Lymphatic Diseases
Neoplasms
Immunoproliferative Disorders
Neoplasms by Histologic Type

Immune System Diseases
Lymphoproliferative Disorders
Lymphoma

ClinicalTrials.gov processed this record on May 07, 2009